Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravitreal injection
|
| gptkbp:approvedBy |
gptkb:FDA
2019 |
| gptkbp:ATCCode |
S01LA05
|
| gptkbp:brand |
gptkb:Beovu
|
| gptkbp:CASNumber |
1610766-54-6
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C2048H3146N564O637S12
|
| https://www.w3.org/2000/01/rdf-schema#label |
brolucizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGF-A inhibition
|
| gptkbp:product |
single-chain antibody fragment
|
| gptkbp:routeOfAdministration |
intravitreal
|
| gptkbp:sideEffect |
intraocular inflammation
retinal vascular occlusion retinal vasculitis |
| gptkbp:target |
gptkb:VEGF-A
|
| gptkbp:UNII |
Q1KQX7K1F1
|
| gptkbp:usedFor |
gptkb:neovascular_age-related_macular_degeneration
|
| gptkbp:bfsParent |
gptkb:Beovu
|
| gptkbp:bfsLayer |
6
|